Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
MULTICENTER STUDY
Dorey A Glenn, Candace D Henderson, Michelle O'Shaughnessy, Yichun Hu, Andrew Bomback, Keisha Gibson, Larry A Greenbaum, Jarcy Zee, Laura Mariani, Ronald Falk, Susan Hogan, Amy Mottl
BACKGROUND AND OBJECTIVES: Infections contribute to patient morbidity and mortality in glomerular disease. We sought to describe the incidence of, and identify risk factors for, infection-related acute care events among Cure Glomerulonephropathy Network (CureGN) study participants. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: CureGN is a prospective, multicenter, cohort study of children and adults with biopsy sample-proven minimal change disease, FSGS, membranous nephropathy, or IgA nephropathy/vasculitis...
December 7, 2020: Clinical Journal of the American Society of Nephrology: CJASN
#22
REVIEW
Ji Woon Oh, Sung Eun Rha, Moon Hyung Choi, Soon Nam Oh, Seo Yeon Youn, Joon-Il Choi
Immunoglobulin G4-related disease (IgG4-RD) is a systemic fibroinflammatory disease characterized by focal or diffuse organ infiltration of IgG4-bearing plasma cells. The diagnosis of IgG4-RD is based on a combination of clinical, serologic, radiologic, and histopathologic findings. IgG4-RD has been reported to affect almost all organ systems. The kidney is the most frequently involved of the genitourinary organs. The most common renal manifestation of IgG4-RD is IgG4-RD tubulointerstitial nephritis, followed by membranous glomerulonephropathy and, less frequently, obstructive nephropathy involving the renal pelvis, ureter, or retroperitoneum...
September 2020: Radiographics: a Review Publication of the Radiological Society of North America, Inc
#23
JOURNAL ARTICLE
Huanhuan Zhu, Huiting Wan, Lin Wu, Qing Li, Simeng Liu, Suyan Duan, Zhimin Huang, Chengning Zhang, Bo Zhang, Changying Xing, Yanggang Yuan
BACKGROUND: Mitochondrial dysfunction contributes to the pathogenesis of diabetic nephropathy (DN). Mitochondrial pyruvate carrier 1 (MPC1) and mitochondrial pyruvate carrier 2 (MPC2) play a bottleneck role in the transport of pyruvate into mitochondrial across the mitochondrial inner membrane. A previous study showed that increasing mitochondrial pyruvate carrier content might ameliorate diabetic kidney disease in db/db mice. However, the expression status of MPC1 and MPC2 in patients with DN is unclear...
July 14, 2020: BMC Nephrology
#24
JOURNAL ARTICLE
Elisa Delbarba, Maddalena Marasa, Pietro A Canetta, Stacy E Piva, Debanjana Chatterjee, Byum Hee Kil, Xueru Mu, Keisha L Gibson, Michelle A Hladunewich, Jonathan J Hogan, Bruce A Julian, Jason M Kidd, Louis-Philippe Laurin, Patrick H Nachman, Michelle N Rheault, Dana V Rizk, Neil S Sanghani, Howard Trachtman, Scott E Wenderfer, Ali G Gharavi, Andrew S Bomback
INTRODUCTION: Glomerular diseases are characterized by variable disease activity over many years. We aimed to analyze the relationship between clinical disease activity and duration of glomerular disease. METHODS: Disease activity in adults with chronic minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy (IgAN; first diagnostic biopsy >5 years before enrollment; Of Longstanding Disease [OLD] cohort, n = 256) followed at Columbia University Medical Center (CUMC), was compared with disease activity of an internal and external cohort of patients with first diagnostic biopsy <5 years before enrollment drawn from the Cure Glomerulonephropathy Network (CureGN cohort, n = 1182; CUMC-CureGN cohort, n = 362)...
June 2020: KI Reports
#25
JOURNAL ARTICLE
Michelle M O'Shaughnessy, Jonathan P Troost, Andrew S Bomback, Michelle A Hladunewich, Isa F Ashoor, Keisha L Gibson, Raed Bou Matar, David T Selewski, Tarak Srivastava, Michelle N Rheault, Amira Al-Uzri, Amy J Kogon, Myda Khalid, Suzanne Vento, Neil S Sanghani, Brenda W Gillespie, Debbie S Gipson, Chia-Shi Wang, Afshin Parsa, Lisa Guay-Woodford, Louis-Philippe Laurin
INTRODUCTION: The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis recommend that patients with membranous nephropathy (MN) at risk for progression receive immunosuppressive therapy (IST), usually after 6 months of observation. A cyclophosphamide (CYC) or calcineurin inhibitor (CNI)-based regimen is recommended as first-line IST. However, the extent to which KDIGO recommendations are adopted in practice remains largely unknown...
December 2019: KI Reports
#26
JOURNAL ARTICLE
Taisuke Irifuku, Ayaka Satoh, Hiroki Tani, Kouichi Mandai, Takao Masaki
Nivolumab is an anti-programmed cell death-1 antibody that is utilized as an immune checkpoint inhibitor for several malignancies. However, this agent is associated with immune-related adverse events (irAEs), mainly in the spectrum of autoimmune disease including interstitial pneumonia, colitis, type 1 diabetes, and renal impairment. We herein present the case of a 59-year-old man with renal cell carcinoma who developed worsening renal function approximately 4 months after initiation of nivolumab. Urinalysis showed proteinuria and microscopic hematuria along with increase levels of N-acetyl-β-D-glucosaminidase...
February 2020: CEN Case Reports
#27
JOURNAL ARTICLE
Hiroki Tanaka, Kie Horioka, Masahiro Yamamoto, Masaru Asari, Katsuhiro Okuda, Kosuke Yamazaki, Keiko Shimizu, Katsuhiro Ogawa
In hepatocarcinogenesis induced by diethylnitrosamine (DEN) in B6C3F1 mice, the BrafV637E mutation, corresponding to the human BRAFV600E mutation, plays a pivotal role. The livers of transgenic mice with a hepatocyte-specific human BRAFV600E mutation weighed 4.5 times more than that of normal mice and consisted entirely of hepatocytes, resembling DEN-induced preneoplastic hepatocytes. However, these transgenic mice spontaneously died 7 wk after birth, therefore this study aimed to clarify the causes of death...
September 2019: Cancer Science
#28
JOURNAL ARTICLE
Isa F Ashoor, Sarah A Mansfield, Michelle M O'Shaughnessy, Rulan S Parekh, Jarcy Zee, Tetyana L Vasylyeva, Amy J Kogon, Christine B Sethna, Dorey A Glenn, Aftab S Chishti, Donald J Weaver, Margaret E Helmuth, Hilda E Fernandez, Michelle N Rheault
Background Cardiovascular disease is a major cause of morbidity and mortality in children with chronic kidney disease. We sought to determine the prevalence of cardiovascular risk factors in children with glomerular disease and to describe current practice patterns regarding risk factor identification and management. Methods and Results Seven-hundred sixty-one children aged 0 to 17 years with any of 4 biopsy-confirmed primary glomerular diseases (minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy/vasculitis) were enrolled at a median of 16 months from glomerular disease diagnosis in the multicenter prospective Cure Glomerulonephropathy Network study...
July 16, 2019: Journal of the American Heart Association
#29
Nosheen Anjum, Zahid Nabi, Muhammad Adeel Alam
This is the time of paradigm shift in the treatment of primary membranous nephropathy which carries a major position in causing nephrotic syndrome in adult population and has been labelled as a cause of idiopathic primary glomerulonephropathy in about 90% of patients. It is two folds more common in male population as compared to female population. It is held responsible for about 0.7% cases of end stage kidney disease. However, unfortunately, the optimal treatment for idiopathic membranous nephropathy is still unresolved...
April 2019: Journal of Ayub Medical College, Abbottabad: JAMC
#30
MULTICENTER STUDY
Pietro A Canetta, Jonathan P Troost, Shannon Mahoney, Amy J Kogon, Noelle Carlozzi, Sharon M Bartosh, Yi Cai, T Keefe Davis, Hilda Fernandez, Alessia Fornoni, Rasheed A Gbadegesin, Emily Herreshoff, John D Mahan, Patrick H Nachman, David T Selewski, Christine B Sethna, Tarak Srivastava, Katherine R Tuttle, Chia-Shi Wang, Ronald J Falk, Ali G Gharavi, Brenda W Gillespie, Larry A Greenbaum, Lawrence B Holzman, Matthias Kretzler, Bruce M Robinson, William E Smoyer, Lisa M Guay-Woodford, Bryce Reeve, Debbie S Gipson
There is scant literature describing the effect of glomerular disease on health-related quality of life (HRQOL). The Cure Glomerulonephropathy study (CureGN) is an international longitudinal cohort study of children and adults with four primary glomerular diseases (minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy). HRQOL is systematically assessed using items from the Patient-Reported Outcomes Measurement Informative System (PROMIS). We assessed the relationship between HRQOL and demographic and clinical variables in 478 children and 1115 adults at the time of enrollment into CureGN...
May 2019: Kidney International
#31
LETTER
Sandeep Arora, Anantharam Jairam, S Radhakrishnan, Niyor Das, Mahesha Vankalakunti
No abstract text is available yet for this article.
November 2019: Indian Journal of Dermatology, Venereology and Leprology
#32
JOURNAL ARTICLE
Cristina Barbagallo, Roberta Passanisi, Federica Mirabella, Matilde Cirnigliaro, Arianna Costanzo, Giovanni Lauretta, Davide Barbagallo, Cristina Bianchi, Fabio Pagni, Sergio Castorina, Antonio Granata, Cinzia Di Pietro, Marco Ragusa, Lorenzo S Malatino, Michele Purrello
Membranous glomerulonephropathy (MGN) is a glomerulopathy characterized by subepithelial deposits of immune complexes on the extracapillary side of the glomerular basement membrane. Insertion of C5b-9 (complement membrane-attack complex) into the membrane leads to functional impairment of the glomerular capillary wall. Knowledge of the molecular pathogenesis of MGN is actually scanty. MicroRNA (miRNA) profiling in MGN and unaffected tissues was performed by TaqMan Low-Density Arrays. Expression of miRNAs and miRNA targets was evaluated in Real-Time polymerase chain reaction (PCR)...
December 4, 2018: Journal of Cellular Physiology
#33
JOURNAL ARTICLE
David T Selewski, Josephine M Ambruzs, Gerald B Appel, Andrew S Bomback, Raed Bou Matar, Yi Cai, Daniel C Cattran, Aftab S Chishti, Vivette D D'Agati, Cynthia J D'Alessandri-Silva, Rasheed A Gbadegesin, Jonathan J Hogan, Sandra Iragorri, J Charles Jennette, Bruce A Julian, Myda Khalid, Richard A Lafayette, Helen Liapis, Francesca Lugani, Sarah A Mansfield, Sherene Mason, Patrick H Nachman, Cynthia C Nast, Carla M Nester, Damien G Noone, Jan Novak, Michelle M O'Shaughnessy, Heather N Reich, Michelle N Rheault, Dana V Rizk, Manish K Saha, Neil S Sanghani, C John Sperati, Rajasree Sreedharan, Tarak Srivastava, Agnieszka Swiatecka-Urban, Katherine Twombley, Tetyana L Vasylyeva, Donald J Weaver, Hong Yin, Jarcy Zee, Ronald J Falk, Ali G Gharavi, Brenda W Gillespie, Debbie S Gipson, Larry A Greenbaum, Lawrence B Holzman, Matthias Kretzler, Bruce M Robinson, William E Smoyer, Michael Flessner, Lisa M Guay-Woodford, Krzysztof Kiryluk
Introduction: The Cure Glomerulonephropathy Network (CureGN) is a 66-center longitudinal observational study of patients with biopsy-confirmed minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (IgAN), including IgA vasculitis (IgAV). This study describes the clinical characteristics and treatment patterns in the IgA cohort, including comparisons between IgAN versus IgAV and adult versus pediatric patients. Methods: Patients with a diagnostic kidney biopsy within 5 years of screening were eligible to join CureGN...
November 2018: KI Reports
#34
JOURNAL ARTICLE
John J Sim, Simran K Bhandari, Michael Batech, Aviv Hever, Teresa N Harrison, Yu-Hsiang Shu, Dean A Kujubu, Tracy Y Jonelis, Michael H Kanter, Steven J Jacobsen
OBJECTIVE: To compare renal function decline, incident end-stage renal disease (ESRD), and mortality among patients with 5 common glomerular diseases in a large diverse population. PATIENTS AND METHODS: A retrospective cohort study (between January 1, 2000, and December 31, 2011) of patients with glomerulonephropathy using the electronic health record of an integrated health system was performed. Estimated glomerular filtration rate (eGFR) change, incident ESRD, and mortality were compared among patients with biopsy-proven focal segmental glomerulosclerosis (FSGS), membranous glomerulonephritis (MN), minimal change disease (MCD), immunoglobulin A nephropathy (IgAN), and lupus nephritis (LN)...
February 2018: Mayo Clinic Proceedings
#35
JOURNAL ARTICLE
Isaac E Lloyd, Faris Ahmed, Monica P Revelo, Mazdak A Khalighi
Immune complex deposition in kidney allografts can include both recurrent and de novo processes. Recurrent glomerulonephritis is a well-recognized phenomenon and has been shown to be a common cause of allograft failure. De novo immune complex-mediated disease remains relatively poorly characterized, likely owing to the less frequent use of immunofluorescence and electron microscopy in the transplant setting. We performed a retrospective review of kidney allograft biopsies showing glomerular immune complex deposition...
January 2018: Human Pathology
#36
REVIEW
Ke Zheng, Fei Teng, Xue-Mei Li
Immunoglobulin G4-related disease (IgG4-RD) is a recently recognized clinical entity that often involves multiple organs; it is characterized by high levels of serum immunoglobulin G4 (IgG4), dense infiltration of IgG4+ cells, and storiform fibrosis. Cellular immunity, particularly T cell-mediated immunity, has been implicated in the pathogenesis of IgG4-RD. The most frequent renal manifestations of IgG4-RD are IgG4-related tubulointerstitial nephritis, membranous glomerulonephropathy (MGN), and obstructive nephropathy secondary to urinary tract obstruction due to IgG4-related retroperitoneal fibrosis, prostatitis, or ureter inflammation...
September 2017: Chronic Diseases and Translational Medicine
#37
JOURNAL ARTICLE
Naoaki Yamada, Nanako Hashimoto, Junichi Kamiie, Takuya Doi, Junko Sato, Takeshi Inoue, Kinji Shirota, Minoru Tsuchitani
The authors previously investigated progressive glomerulonephropathy in 2- to 11-year-old common marmosets and characterized age-related changes of the renal glomeruli and development of tubulointerstitial lesions. In this study, immunoglobulin deposition and ultrastructural changes of the glomeruli were investigated in 5 young marmosets from 6 months to 3 years of age with pre-onset or early glomerulonephropathy. In all animals, the foot processes of podocytes were effaced, and IgM was deposited into the glomeruli...
January 2018: Veterinary Pathology
#38
JOURNAL ARTICLE
Misa Ikeda, Hirokazu Honda, Naoto Kobayashi, Shoko Onuma, Kei Matsumoto, Tadao Akizawa, Yutaka Yamaguchi, Takanori Shibata
Bullous pemphigoid (BP) is a common autoimmune blistering disease that can be complicated by autoimmune disorders. We describe a patient with BP who developed membranous glomerulonephropathy (MN). Proteinuria decreased during the clinical course as anti-BP180 antibody titers decreased. This finding suggested an association between the pathogenesis of these two diseases in terms of immunological disorders.
May 2017: CEN Case Reports
#39
JOURNAL ARTICLE
Srikanth Prasad Devarsetty, Dharshan Rangaswamy, Shailaja Bhat, Shankar Prasad Nagaraju, Ravindra Prabhu Attur
Paraneoplastic glomerulopathy has been described in established cases of the solid tumors of lung, gastrointestinal system, breast, etc., and rarely in patients with Renal Cell Carcinoma (RCC). Studies on secondary glomerular diseases have described a higher incidence of IgA nephropathy in patients with RCC compared to membranous glomerulopathy, which are commonly reported in malignancies of the lung and gastrointestinal tract. Collecting Duct Carcinoma (CDC), a rare high grade adenocarcinoma accounts for <1% of all renal malignancies...
February 2017: Journal of Clinical and Diagnostic Research: JCDR
#40
JOURNAL ARTICLE
Amrit Kirpalani, Michael J Rieder, Kevin C Bax, Guido Filler
An infant boy with steroid-resistant nephrotic syndrome (idiopathic membranous glomerulonephropathy) achieved remission with ciclosporin but developed eosinophilia and high IgE levels (max 19 000 iU/mL). Conversion to tacrolimus resulted in chronic diarrhoea (eosinophilic gastroenteritis), muscle weakness, polyserositis and failure-to-thrive. In contrast, a trial without tacrolimus resulted in a ciclosporin-responsive relapse, therapy-resistant focal seizures with generalised spikes, worsening muscle weakness and diarrhoea...
January 30, 2017: BMJ Case Reports
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
